2020년 세계 줄기세포 시장 규모는 143억 7,000만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 10.34%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 258억 달러에 달할 것으로 예상됩니다. 줄기세포 시장은 다양한 만성질환의 유병률 증가와 이에 대한 신약개발 수요 증가, 줄기세포 연구 활동의 활성화, 유전성 질환 환자 수 증가, 전 세계 줄기세포 치료의 보급 등으로 인해 긍정적인 성장을 보이고 있습니다. 또한, 생물학적 제제에 대한 수요 증가, 이 분야의 첨단 제품 개발에 대한 관심 증가도 줄기세포 세계 시장을 견인하는 요인 중 하나입니다.
줄기세포 시장은 여러 가지 이유로 제품 수요가 증가하고 있는데, 그 주요 요인 중 하나는 다양한 만성질환의 유병률 증가와 신약개발에 대한 수요가 증가하고 있으며, 1형 당뇨병, 파킨슨병, 알츠하이머병과 같은 신경퇴행성 질환의 치료제로서 세포이식이 이미 연구되고 있습니다. 연구되고 있습니다. 예를 들어, 2022년 1월 블루락 테라퓨틱스(BlueRock Therapeutics)의 세포 기반 파킨슨병 치료제 DA01의 임상 1상 시험에서 캐나다에서 첫 환자가 투약되었습니다.
이러한 질환에 대한 전임상 효과를 바탕으로 이 기술은 현재 AD, 근위축성 측색경화증, 헌팅턴병과 같은 다른 신경 퇴행성 질환에도 적용되고 있으며, WHO에 따르면 2020년까지 만성 질환의 유병률이 57% 증가할 것으로 예상되고 있습니다. 만성질환의 유병률이 증가함에 따라 줄기세포를 이용한 치료를 선택하는 사람들이 증가하여 시장 성장의 원동력이 될 것입니다. 따라서 다양한 만성질환의 확산과 의약품 개발과 관련된 연구 활동은 예측 기간 동안 줄기세포 치료에 대한 수요 증가로 이어져 줄기세포 시장의 성장을 견인할 것으로 예상됩니다.
이 보고서는 세계 줄기세포 시장을 조사했으며, 시장 개요와 함께 제품 유형별, 용도별, 치료 유형별, 용도별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Stem Cell Market By Product Type (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, Others), By Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Injuries And Wounds, Cardiovascular Disorders, Others), By Therapy Type (Allogeneic Stem Cell Therapy, Autologic Stem Cell Therapy), By Usage (Regenerative Medicine, Drug Discovery And Development), by geography is expected to grow at a steady CAGR forecast till 2030 owing to growing stem cell research activities and need for drug discovery
Global Stem Cell Market was valued at USD 14.37 billion in 2020, growing at a CAGR of 10.34% during the forecast period from 2024 to 2030 to reach USD 25.80 billion by 2030. The Stem Cell market is witnessing positive growth owing to the rising prevalence of various chronic diseases and the need for their drug discovery, growing stem cell research activities, increasing cases of genetic disorders, significant adoption of stem cell therapies globally. In addition, increasing demand for biologics, accumulative focus on developing advanced products in the arena are some of the factors contributing to the Global Stem Cell Market.
Stem Cell Market Dynamics:
The Stem Cell market is witnessing a growth in product demand owing to various reasons, one of the key factors being the rising prevalence of various chronic diseases and the significant need for their drug discovery. Cell transplantation as a therapy for neurodegenerative disorders such as Diabetes type 1, Parkinson's disease, and Alzheimer's disease among others are already being explored. For instance, in January 2022, the first patient in Canada has been dosed in a Phase 1 clinical trial of DA01, a cell-based investigational therapy for advanced Parkinson's disease by BlueRock Therapeutics.
Based on the preclinical effect in these diseases, the technique is now being applied to other neurodegenerative disorders, such as AD, amyotrophic lateral sclerosis, and Huntington's disease. According to WHO, by 2020, the prevalence of the chronic disease is predicted to increase by 57%. As the prevalence of chronic disease increases, people opting for stem cell-based treatment will rise, thus driving the market growth. Therefore, the prevalence of various chronic diseases and their research activities involved in drug development, in turn, would lead to an increase in demand for Stem Cell therapies in the forecast period (2024-2030), which will drive the Stem Cell market growth.
Another key factor responsible for the growth of the Stem Cell market is the increasing cases of genetic disorders. As genetic disorders occur due to anomalies of genetic origin, there has been a growing demand for stem cell therapies. Stem Cell therapy holds promise for treating a wide range of diseases, such as Cancer, Neonatal Encephalopathy, among others. For instance, on June 11, 2019, Mesoblast Limited announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan for the use of mesenchymal stem cells (MSCs) in the treatment of newborns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic-ischemic encephalopathy (HIE).
Hence, Stem Cell therapy-based biologics have a wide range of applications, from gene replacement to gene knockdown.
Furthermore, stem cell therapy offers a more sustainable treatment approach, thereby becoming one of the popular choices in the management of genetic diseases. This results in a large number of potential stem cell therapies being under clinical development. This indicates the plethora of potential therapies that may reach the market in the coming years. Hence, growing stem cell research activities is another key factor being responsible for further boosting the growth of the Stem Cell market during the forecast period.
Thus, all the aforementioned factors are expected to augment the global market for Stem Cell.
However, ethical issues related to the use of stem cells and the high cost of these therapies is likely to impede the market growth.
Along with the factors mentioned above, the COVID-19 pandemic presented another major opportunity for growth for the manufacturers operating in the biopharmaceutical domain. The effect of the pandemic accelerated the drug development activities for the SARS-Cov-2 virus across the globe. The dire need for developing a vaccine to contain the pandemic led to the approval and emergency use authorization of numerous vaccines for prophylactic use across the globe. Moreover, some of the recent studies have suggested that stem cell therapy has a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Therefore, different candidates under development might prove as a potential therapy for COVID-19 infection.
Stem Cell Market Segment Analysis:
Stem Cell Market By Product Type (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, Others), By Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Injuries and Wounds, Cardiovascular Disorders, Others), By Therapy Type (Allogeneic Stem Cell Therapy, Autologic Stem Cell Therapy), By Usage (Regenerative Medicine, Drug Discovery and Development), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the Therapy Type segment of the Stem Cell Market, Allogeneic Stem Cell Therapy is estimated to hold the highest share in the Stem Cell market during the forecast period (2024-2030).
Allogeneic Stem Cell Therapy offers several advantages as they are derived from a donor whose human leukocyte antigens (HLA) are acceptable matches to the patients. The stem cell donor may be related to the patient, or they may be an unrelated volunteer found through a donor registry.
Moreover, the growth of the segment is attributed to the easy process of manufacturing & production and the increasing availability of novel stem cell products across major countries.
Also, this therapy is widely used for treating different types of cancers such as lymphomas, leukemias, and myelomas.
Therefore, considering the advantages associated with Allogeneic Stem Cell Therapy, this product category is expected to generate significant revenue share eventually contributing to the overall growth of the global Stem Cell market in the forecast period.
North America is expected to dominate the overall Stem Cell Market:
Among all the regions, North America is expected to account for the largest share in the Global Stem Cell market. This can be ascribed to the high focus on therapy development for rare genetic diseases, growing stem cell research activities, a growing focus on the development of personalized medicines, supportive regulatory environment, sophisticated healthcare infrastructure, and increased awareness and product launches regarding new treatments are also expected to aid in the Stem Cell market growth in this region.
One of the key supporting factors for the growth of the North America Stem Cell market is the increasing focus on developing therapies for rare genetic diseases, particularly in the United States. As per the data provided by the US Food and Drug Administration (FDA) (2023), there are more than 7,000 rare diseases that affect more than 30 million people in the United States. The huge number of indications has resulted in a considerable number of companies in the country developing therapeutics aimed at treating genetic diseases. Therefore, the increasing focus of the US FDA and the US government in catering to the medical needs of people suffering from diseases in the country is also expected to drive the North America Stem Cell market in coming years.
Furthermore, an active pipeline by key players being involved in the development of such products is anticipated to fuel the market in the region.
Moreover, the occurrence of various strategic business activities in the region such as company collaborations, acquisitions, product launch, and approval, among others are also expected to propel the market for Stem Cell in the region. For instance, on March 12, 2019, Smith & Nephew plc announced its acquisition of Osiris Therapeutics, Inc., which is a company delivering regenerative medicine products, including skin, bone graft, and articular cartilage substitutes, for approximately USD 660 million. This in turn would provide a conducive growth environment for the North America region.
These kinds of products launched in the local markets will thereby push the product demand in the market. Therefore, the interplay of various factors in the region is expected to boost the North America Stem Cell market during the forecast period.
Stem Cell Market Key Players:
Some of the key market players operating in the Stem Cell market include Osiris Therapeutics, Inc. (Smith+Nephew Inc.), MEDIPOST Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., JCR Pharmaceuticals Co. Ltd., NuVasive®, Inc., Stempeutics Research Pvt Ltd., Bristol-Myers Squibb Company, Organogenesis Inc., Takeda Pharmaceutical Company Limited, CHIESI SAS, Tegoscience, Biosolution Co., Ltd., CORESTEM, Inc., CO.DON, NIPRO and others.
Recent Developmental Activities in the Stem Cell Market:
On 17 May 2022, MEDIPOST completed the expansion of its production facilities for its knee osteoarthritis stem cell products, CARTISTEM® and SMUP-IA-01, and will start to prepare for GMP (Good Manufacturing Practice) certification.
On February 5, 2022, Bristol Myers won FDA approval for its cancer cell therapy, Breyanzi, for the treatment of late-stage lymphoma.
In August 2020, Cipla Limited announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval from the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.
Key Takeaways from the Stem Cell Market Report Study
Target Audience who can be benefited from this Stem Cell Market Report Study
Frequently Asked Questions for Stem Cell Market:
Stem cell therapy, also known as regenerative medicine, promotes the repair response of diseased, dysfunctional, or injured tissue using stem cells or their derivatives. It is the next step in organ transplantation and uses cells instead of donor organs, which are limited in supply.
Global Stem Cell Market was valued at USD 14.37 billion in 2020, growing at a CAGR of 10.34% during the forecast period from 2024 to 2030 to reach USD 25.80 billion by 2030.
The Stem Cell market is witnessing a positive market growth owing to the rising prevalence of various chronic diseases and the need for their drug discovery, growing stem cell research activities, increasing cases of genetic disorders, significant adoption of stem cell therapies globally. In addition, increasing demand for biologics, accumulative focus on developing advanced products in the arena.
Some of the key market players operating in the Stem Cell market include Osiris Therapeutics, Inc. (Smith+Nephew Inc.), MEDIPOST Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., JCR Pharmaceuticals Co. Ltd., NuVasive®, Inc., Stempeutics Research Pvt Ltd., Bristol-Myers Squibb Company, Organogenesis Inc., Takeda Pharmaceutical Company Limited, CHIESI SAS, Tegoscience, Biosolution Co., Ltd., CORESTEM, Inc., CO.DON, NIPRO, and others.
North America is expected to hold the highest share in the revenue in the Stem Cell market during the forecast period. This can be ascribed to the high focus on therapy development for rare genetic diseases, growing stem cell research activities, a growing focus on the development of personalized medicines, supportive regulatory environment, sophisticated healthcare infrastructure, and increased awareness and product launches regarding new treatments are also expected to aid in the Stem Cell market growth in this region.